PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Clinical trials for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Drug cocktail shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
Virus plus immunotherapy shows promise against resistant ovarian cancer
Disease control OngoingThis early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC